3-deazaneplanocin has been researched along with Glioblastoma in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Castresana, JS; De La Rosa, J; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A; Zazpe, I; Zelaya, MV | 2 |
Han, L; Jiang, K; Kang, C; Liu, X; Ning, X; Shi, Z; Zhang, A; Zhang, Q | 1 |
3 other study(ies) available for 3-deazaneplanocin and Glioblastoma
Article | Year |
---|---|
The synergistic effect of DZ‑NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Panobinostat; Temozolomide; Tumor Cells, Cultured | 2020 |
APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Drug Screening Assays, Antitumor; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mutation; Panobinostat; Quinuclidines; Temozolomide; Tumor Suppressor Protein p53 | 2021 |
DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
Topics: Adenosine; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Histones; Humans; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Polycomb Repressive Complex 2; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |